1PHQ-9 Score Interpretation & Stepped Care
| Score | Severity Tier | Clinical Action & Stepped-Care Plan |
|---|---|---|
| 0–4 | Minimal | No formal intervention required. Provide general wellness guidance and sleep hygiene advice. |
| 5–9 | Mild | Watchful waiting and psychoeducation. Guided self-help CBT and exercise. Re-evaluate in 4 weeks. |
| 10–14 | Moderate | Validated clinical cutoff (≥10). Formulate active treatment plan: structured CBT, consider SSRI pharmacotherapy. Review in 2 weeks. |
| 15–19 | Moderately Severe | Active treatment indicated: initiate first-line SSRI medication and refer for high-intensity psychological therapy. Regular safety monitoring. |
| 20–27 | Severe | Immediate pharmacotherapy initiation. Urgent psychiatric referral. Comprehensive suicide safety assessment and consider crisis team involvement. |
2PHQ-9 Item 9 — Mandatory Suicide Risk Assessment
- Active vs. passive suicidal ideation.
- Presence of a specific plan, timeline, and intent to act.
- Access to lethal means (medications, firearms, heights).
- Past history of self-harm or suicide attempts.
- Protective factors, social support, and formulation of an emergency safety plan.
3GAD-7 Score Interpretation
| Score | Severity Tier | Clinical Action Plan |
|---|---|---|
| 0–4 | Minimal Anxiety | Reassurance; lifestyle optimization; stress-reduction techniques. |
| 5–9 | Mild Anxiety | Psychoeducation, sleep hygiene, mindfulness, and guided self-help. Review in 4–6 weeks. |
| 10–14 | Moderate Anxiety | Clinical cutoff (≥10). Refer for structured Cognitive Behavioral Therapy (CBT). Consider SSRI initiation. Rule out somatic causes (thyroid dysfunction, arrhythmias, caffeine excess). |
| 15–21 | Severe Anxiety | Combined SSRI pharmacotherapy and intensive CBT. Psychiatric consultation if panic attacks or severe functional disability are present. |
A positive PHQ-9 or GAD-7 screen can prompt further clinical assessment, but accessing the recommended care involves another set of practical teps: finding an available provider, confirming insurance coverage, and understanding the likely cost. For patients in the United States, Rula is a behavioral health platform offering access to therapy and psychiatric care through a nationwide network of more than 22,000 licensed providers.
Rula verifies insurance and provides copay estimates before booking. Matching considers submitted preferences—including gender, age range, identity and ethnicity, religion, and language—alongside insurance acceptance and appointment availability. Next-day appointments may be available,depending on the patient’s location, plan, and provider.
For patients whose clinician recommends therapy, medication management, or both, having access to these services through one platform can simplify the search for care. Screening scores alone do not establish a diagnosis or determine treatment; the appropriate plan requires an individual clinical assessment.
4First-Line Evidence-Based Treatments
- Escitalopram: 10 mg once daily (high selectivity, favorable tolerability).
- Sertraline: 50 mg once daily (safest profile in cardiovascular disease and elderly).
- Fluoxetine: 20 mg once daily (long half-life, low discontinuation syndrome risk).
- Duration: Allow 4–6 weeks for therapeutic response. Continue for a minimum of 6–12 months after remission to prevent relapse.
- Cognitive Behavioral Therapy (CBT): 8–16 structured individual sessions. First-line for depression and GAD; superior to pharmacotherapy in preventing long-term relapse.
- Mindfulness-Based Cognitive Therapy (MBCT): Recommended for recurrent depressive episodes (≥3 lifetime episodes).
- Combined Approach: For moderate-to-severe presentations, combined SSRI + CBT yields superior recovery rates over monotherapy.